Dupont Capital Management Corp Tg Therapeutics, Inc. Transaction History

Dupont Capital Management Corp

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jan 26, 2023	SELL	$5.01 - $11.83 $10,145 - $23,955	-2,025 Reduced 9.68%	18,889 $0
Q3 2022 Oct 31, 2022	BUY	$4.57 - $8.4 $95,576 - $175,677	20,914 New	20,914 $124,000
Q3 2018 Nov 05, 2018	SELL	$5.15 - $14.0 $244,388 - $664,356	-47,454 Closed	0 $0
Q2 2018 Jul 30, 2018	SELL	$12.5 - $15.0 $137,087 - $164,505	-10,967 Reduced 18.77%	47,454 $624,000
Q1 2018 May 02, 2018	SELL	$8.7 - $16.8 $56,863 - $109,804	-6,536 Reduced 10.06%	58,421 $830,000
Q4 2017 Jan 31, 2018	BUY	$7.35 - $12.3 $288,818 - $483,328	39,295 Added 153.13%	64,957 $533,000
Q3 2017 Oct 31, 2017	BUY	$10.0 - $12.7 $256,620 - $325,907	25,662	25,662 $304,000

349

89.5M

2.35M

1.7M

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $4.61B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

Get notified when there are updates to the investment portfolio of Dupont Capital Management Corp, based on Form 13F filings with the SEC.

Stay updated on Dupont Capital Management Corp with notifications on news.